(CercleFinance.com) – AstraZeneca announced on Monday that the Chinese Medicines Agency had approved Koselugo, developed as part of its partnership with the American Merck, for the treatment of neurofibromatosis type I.
The laboratory points out that the green light from the Chinese Medical Products Administration (NMPA) was based on clinical results which showed that the drug, administered orally, made it possible to reduce the size of inoperable tumors in children.
Neurofibromatosis type I – or NF1 – is a rare and progressive genetic disease that affects one in 3000 individuals worldwide and is most often diagnosed in children under the age of 10.
In 30% to 50% of patients, it results in tumors that grow on the nerve sheaths (plexiform neurofibromas) and cause clinical problems such as disfigurement, motor dysfunction, pain, airway dysfunction, visual impairment, and motor dysfunction. bladder or bowel.
Koselugo, which is subject to a co-development and co-commercialization agreement with Merck, has already been approved in the United States, Europe and Japan and is currently under review in other countries. .
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
